{"id":917383,"date":"2025-12-08T09:21:26","date_gmt":"2025-12-08T14:21:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/"},"modified":"2025-12-08T09:21:26","modified_gmt":"2025-12-08T14:21:26","slug":"caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/","title":{"rendered":"CALDOLOR\u00ae (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NASHVILLE, Tenn.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Dec. 8, 2025<\/span><\/span> \/PRNewswire\/ &#8212; <b>Cumberland Pharmaceuticals Inc.<\/b> (Nasdaq: CPIX), today announced an important update regarding its Caldolor<sup>\u00ae<\/sup> (ibuprofen) Injection. The product&#8217;s permanent <b>J-code, J1741<\/b>, is now officially associated with a reimbursement price, providing healthcare providers with a CMS-covered, non-opioid option for managing pain and fever.<\/p>\n<p>As the nation continues to face an opioid crisis, non-opioid alternatives, like Caldolor, play a critical role in reducing reliance on opioid medications, supporting safer pain management strategies for patients. With the reimbursement price now linked to J1741, providers can access a CMS-covered, non-opioid pain management option and align treatment strategies with opioid-sparing initiatives.<\/p>\n<p>\n        <b>Caldolor J-Code Details: <\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Product:\u00a0<\/b>Caldolor<sup>\u00ae<\/sup> (ibuprofen) Injection<\/li>\n<li>\n          <b>J-Code: J1741 \u2013 Injection, ibuprofen, 100 mg<\/b>\n        <\/li>\n<li>\n          <b>Status:<\/b> Now associated with reimbursement price<\/li>\n<\/ul>\n<p>&#8220;With Caldolor now linked to an established reimbursement price, healthcare providers have a reimbursable non-opioid alternative to help address pain management,&#8221; said Cumberland Pharmaceuticals CEO <span class=\"xn-person\">A.J. Kazimi<\/span>. &#8220;This update supports providers in making clinically appropriate decisions while contributing to efforts to reduce\u00a0opioid exposure and reinforces our commitment to improving access to Caldolor and ensuring patients receive the pain management they need.&#8221;<\/p>\n<p>Providers are encouraged to update their internal systems, billing teams, and reimbursement processes to reflect this change. For additional support with coding, coverage, or payment questions, please contact your Cumberland Pharmaceuticals representative or email <u><a href=\"mailto:caldolor@cumberlandpharma.com\" target=\"_blank\" rel=\"nofollow\">caldolor@cumberlandpharma.com<\/a><\/u>.<\/p>\n<p>\n        <b><br \/>\n          <u>About Caldolor<sup>\u00ae<\/sup>\u00a0(ibuprofen) Injection<\/u><br \/>\n        <\/b>\n      <\/p>\n<p>Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit\u00a0<u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4574209-1&amp;h=3470634942&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4295494-1%26h%3D2531498238%26u%3Dhttp%253A%252F%252Fwww.caldolor.com%252F%26a%3Dwww.caldolor.com&amp;a=www.caldolor.com\" target=\"_blank\" rel=\"nofollow\">www.caldolor.com<\/a><\/u>.<\/p>\n<p>\n        <b><br \/>\n          <u>About Cumberland Pharmaceuticals<\/u><br \/>\n        <\/b>\n      <\/p>\n<p>Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in <span class=\"xn-location\">Tennessee<\/span> and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company&#8217;s portfolio of FDA-approved brands includes:<\/p>\n<ul type=\"disc\">\n<li>\n          <b>Acetadote<sup>\u00ae<\/sup><\/b> (acetylcysteine) injection, for the treatment of acetaminophen poisoning;<\/li>\n<li>\n          <b>Caldolor<sup>\u00ae<\/sup><\/b> (ibuprofen) injection, for the treatment of pain and fever;<\/li>\n<li>\n          <b>Kristalose<sup>\u00ae<\/sup><\/b> (lactulose) oral, a prescription laxative, for the treatment of constipation;<\/li>\n<li>\n          <b>Sancuso<sup>\u00ae<\/sup><\/b> (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;<\/li>\n<li>\n          <b>Vaprisol<sup>\u00ae<\/sup><\/b>(conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;<\/li>\n<li>\n          <b>Vibativ<sup>\u00ae<\/sup><\/b> (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections, and<\/li>\n<li>\n          <b>Talicia<sup>\u00ae<\/sup><\/b>(<i>omeprazole magnesium, amoxicillin and rifabutin<\/i>) oral capsule, for the treatment of\u00a0<i>H. pylori<\/i>\u00a0infection.<\/li>\n<\/ul>\n<p>The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis.<\/p>\n<p>For more information on <span class=\"xn-location\">Cumberland&#8217;s<\/span> approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company&#8217;s website <u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4574209-1&amp;h=751491527&amp;u=http%3A%2F%2Fwww.cumberlandpharma.com%2F&amp;a=www.cumberlandpharma.com\" target=\"_blank\" rel=\"nofollow\">www.cumberlandpharma.com<\/a><\/u>.<\/p>\n<p>\n        <b><br \/>\n          <u>Forward-Looking Statements<\/u><br \/>\n        <\/b>\n      <\/p>\n<p>This press release contains forward-looking statements, which are subject to certain risks and reflect <span class=\"xn-location\">Cumberland&#8217;s<\/span> current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of <span class=\"xn-location\">Cumberland&#8217;s<\/span> operations are subject to factors outside of its control, and any one or combination of these factors could materially affect <span class=\"xn-location\">Cumberland&#8217;s<\/span> results of operations. These factors include market conditions, competition, an inability of manufacturers to produce <span class=\"xn-location\">Cumberland&#8217;s<\/span> products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company&#8217;s most recent Form 10-K and subsequent 10-Qs as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CL40987&amp;sd=2025-12-08\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management-302634989.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management-302634989.html<\/a><\/p>\n<p>SOURCE  Cumberland Pharmaceuticals Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CL40987&amp;Transmission_Id=202512080905PR_NEWS_USPR_____CL40987&amp;DateId=20251208\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NASHVILLE, Tenn. , Dec. 8, 2025 \/PRNewswire\/ &#8212; Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), today announced an important update regarding its Caldolor\u00ae (ibuprofen) Injection. The product&#8217;s permanent J-code, J1741, is now officially associated with a reimbursement price, providing healthcare providers with a CMS-covered, non-opioid option for managing pain and fever. As the nation continues to face an opioid crisis, non-opioid alternatives, like Caldolor, play a critical role in reducing reliance on opioid medications, supporting safer pain management strategies for patients. With the reimbursement price now linked to J1741, providers can access a CMS-covered, non-opioid pain management option and align treatment strategies with opioid-sparing initiatives. Caldolor J-Code Details: Product:\u00a0Caldolor\u00ae (ibuprofen) Injection J-Code: J1741 \u2013 Injection, ibuprofen, 100 mg Status: Now &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CALDOLOR\u00ae (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-917383","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CALDOLOR\u00ae (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CALDOLOR\u00ae (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NASHVILLE, Tenn. , Dec. 8, 2025 \/PRNewswire\/ &#8212; Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), today announced an important update regarding its Caldolor\u00ae (ibuprofen) Injection. The product&#8217;s permanent J-code, J1741, is now officially associated with a reimbursement price, providing healthcare providers with a CMS-covered, non-opioid option for managing pain and fever. As the nation continues to face an opioid crisis, non-opioid alternatives, like Caldolor, play a critical role in reducing reliance on opioid medications, supporting safer pain management strategies for patients. With the reimbursement price now linked to J1741, providers can access a CMS-covered, non-opioid pain management option and align treatment strategies with opioid-sparing initiatives. Caldolor J-Code Details: Product:\u00a0Caldolor\u00ae (ibuprofen) Injection J-Code: J1741 \u2013 Injection, ibuprofen, 100 mg Status: Now &hellip; Continue reading &quot;CALDOLOR\u00ae (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T14:21:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CL40987&amp;sd=2025-12-08\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CALDOLOR\u00ae (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT\",\"datePublished\":\"2025-12-08T14:21:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\\\/\"},\"wordCount\":781,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=CL40987&amp;sd=2025-12-08\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\\\/\",\"name\":\"CALDOLOR\u00ae (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=CL40987&amp;sd=2025-12-08\",\"datePublished\":\"2025-12-08T14:21:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\\\/#primaryimage\",\"url\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=CL40987&amp;sd=2025-12-08\",\"contentUrl\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=CL40987&amp;sd=2025-12-08\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CALDOLOR\u00ae (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CALDOLOR\u00ae (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/","og_locale":"en_US","og_type":"article","og_title":"CALDOLOR\u00ae (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT - Market Newsdesk","og_description":"PR Newswire NASHVILLE, Tenn. , Dec. 8, 2025 \/PRNewswire\/ &#8212; Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), today announced an important update regarding its Caldolor\u00ae (ibuprofen) Injection. The product&#8217;s permanent J-code, J1741, is now officially associated with a reimbursement price, providing healthcare providers with a CMS-covered, non-opioid option for managing pain and fever. As the nation continues to face an opioid crisis, non-opioid alternatives, like Caldolor, play a critical role in reducing reliance on opioid medications, supporting safer pain management strategies for patients. With the reimbursement price now linked to J1741, providers can access a CMS-covered, non-opioid pain management option and align treatment strategies with opioid-sparing initiatives. Caldolor J-Code Details: Product:\u00a0Caldolor\u00ae (ibuprofen) Injection J-Code: J1741 \u2013 Injection, ibuprofen, 100 mg Status: Now &hellip; Continue reading \"CALDOLOR\u00ae (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-08T14:21:26+00:00","og_image":[{"url":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CL40987&amp;sd=2025-12-08","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CALDOLOR\u00ae (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT","datePublished":"2025-12-08T14:21:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/"},"wordCount":781,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/#primaryimage"},"thumbnailUrl":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CL40987&amp;sd=2025-12-08","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/","name":"CALDOLOR\u00ae (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/#primaryimage"},"thumbnailUrl":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CL40987&amp;sd=2025-12-08","datePublished":"2025-12-08T14:21:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/#primaryimage","url":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CL40987&amp;sd=2025-12-08","contentUrl":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CL40987&amp;sd=2025-12-08"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caldolor-ibuprofen-injection-cms-issued-j-code-now-associated-with-reimbursement-price-supporting-non-opioid-pain-management\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CALDOLOR\u00ae (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917383","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=917383"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917383\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=917383"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=917383"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=917383"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}